This is a best-case data readout that substantially de-risks the gedatolisib program ahead of the July 17 PDUFA. The combination of superior efficacy (2x PFS) and better tolerability vs the current standard-of-care alpelisib positions gedatolisib for potential label expansion into the larger PIK3CA-mutant population. Monitor for sNDA submission timing and any FDA advisory committee meeting. The stock should re-rate upward on the probability of a broad commercial launch in Q3 2026.
CELC drugs
CELC drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $91.42entry
- T+1 · 6mo ago −2.70%α −2.01% · $88.95
- T+5 · 5mo ago +1.28%α +4.24% · $92.59
- T+20 · 5mo ago +14.30%α +15.86% · $104.49
- T+60 · 3mo ago +4.00%α +2.89% · $95.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its gedatolisib-triplet (gedatolisib + fulvestrant + palbociclib) doubled median progression-free survival to 11.1 months vs 5.6 months for alpelisib + fulvestrant (HR=0.50, p<0.0001) in PIK3CA-mutant HR+/HER2- advanced breast cancer, with a 48.9% objective response rate and lower discontinuation rates (2.6% vs 7.1%). The company also noted its existing NDA for the wild-type cohort is under Priority Review with a PDUFA date of July 17, 2026, and it plans to submit these data as an sNDA.
Key Facts
- Gedatolisib-triplet reduced risk of disease progression or death by 50% vs alpelisib + fulvestrant (HR=0.50; 95% CI: 0.37-0.68; p<0.0001)
- Median PFS: 11.1 months (gedatolisib-triplet) vs 5.6 months (alpelisib + fulvestrant)
- Objective response rate: 48.9% (gedatolisib-triplet) vs 26.0% (alpelisib + fulvestrant)
- Treatment discontinuation due to adverse events: 2.6% (gedatolisib-triplet) vs 7.1% (alpelisib + fulvestrant)
- FDA has granted Priority Review for NDA in PIK3CA wild-type ABC with PDUFA goal date of July 17, 2026
- Company plans to submit these data as an sNDA to FDA and to other regulatory authorities
- Company states it is on track for potential FDA approval and commercial launch in Q3 2026
Financial Impact
Transformative for a $6B market cap clinical-stage biotech, gedatolisib now has two positive Phase 3 readouts (WT and MT cohorts) with best-in-class efficacy and safety vs standard-of-care alpelisib, supporting a broad label in HR+/HER2- advanced breast cancer. Peak sales potential is multi-billion dollar if approved in both WT and MT populations.
Risk Factors
- FDA approval is not guaranteed despite Priority Review; a complete response letter would be severely negative
- Commercial launch execution risk for a first-time commercial-stage biotech
- Competition from other PI3K/AKT/mTOR inhibitors in development
- Overall survival data is still immature, a negative OS signal could limit label or uptake
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026761 |
| Document: form8-k.htm | 0001493152-26-026761 |
| Document: 0001493152-26-026761-index-headers.html | 0001493152-26-026761 |
| Document: 0001493152-26-026761-index.html | 0001493152-26-026761 |
| Document: 0001493152-26-026761.txt | 0001493152-26-026761 |
Track record
26 reports on CELC
6 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers